CAS
EDIT icon

Coppell Advisory Solutions’s Editas Medicine EDIT Stock Holding History

Coppell Advisory Solutions’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-85
Closed -$693 – 1287
2023
Q2 		$693 Buy
+85
New +$740 ﹤0.01% 1198

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coppell Advisory Solutions's EDIT Position: Q3 2023 in Review

Coppell Advisory Solutions sold out of Editas Medicine (EDIT) in Q3 2023, closing a stake of 85 shares — an estimated $693 sold.

Coppell Advisory Solutions first reported a position in EDIT in Q2 2023 and held it in 1 quarter. The position peaked at $693 in Q2 2023. 220 funds tracked by Wall St. Rank hold EDIT as of Q3 2023.

  • Coppell Advisory Solutions reported no remaining Editas Medicine position as of Q3 2023 after selling out during the quarter.
  • Coppell Advisory Solutions sold 85 Editas Medicine shares in Q3 2023, an estimated $693.
  • Coppell Advisory Solutions first reported a position in Editas Medicine in Q2 2023 and held it in 1 quarter.
  • Coppell Advisory Solutions's Editas Medicine position peaked at $693 in Q2 2023.
  • 220 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2023.

Based on Coppell Advisory Solutions's 13F filing for Q3 2023, filed 14 Nov 2023.